Literature DB >> 8074453

Human prostate cancer cells: inhibition of proliferation by vitamin D analogs.

G G Schwartz1, T A Oeler, M R Uskoković, R R Bahnson.   

Abstract

1,25-Dihydroxyvitamin D [1,25(OH)2D3, calcitriol] can inhibit the proliferation of some human prostate cancer cells but its clinical use is limited by hypercalcemia. We therefore explored the bioactivity of less calcemic vitamin D analogs. We studied the effects of calcitriol and 3 synthetic analogs at concentrations of 10(-6) to 10(-12) M on the in vitro proliferation of 3 human prostate carcinoma cell lines: DU 145, PC-3, and LNCaP. Calcitriol and analogs showed significant antiproliferative activity on PC-3 and LNCaP cells. DU 145 cells were inhibited by the analogs only. We conclude that vitamin D analogs warrant further investigation as therapeutic agents in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8074453

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  11 in total

Review 1.  Prostate cancer prevention: review of target populations, pathological biomarkers, and chemopreventive agents.

Authors:  R Montironi; R Mazzucchelli; J R Marshall; P H Bartels
Journal:  J Clin Pathol       Date:  1999-11       Impact factor: 3.411

2.  A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer.

Authors:  Kari B Wisinski; Wendy M Ledesma; Jill Kolesar; George Wilding; Glenn Liu; Jeffrey Douglas; Anne M Traynor; Mark Albertini; Daniel Mulkerin; Howard H Bailey
Journal:  J Oncol Pharm Pract       Date:  2014-07-01       Impact factor: 1.809

Review 3.  Rationale for the development and current status of calcitriol in androgen-independent prostate cancer.

Authors:  Tomasz M Beer; Anne Myrthue; Kristine M Eilers
Journal:  World J Urol       Date:  2005-01-25       Impact factor: 4.226

4.  Update on options for treatment of metastatic castration-resistant prostate cancer.

Authors:  Prakash Vishnu; Winston W Tan
Journal:  Onco Targets Ther       Date:  2010-06-24       Impact factor: 4.147

5.  The relation of serum parathyroid hormone and serum calcium to serum levels of prostate-specific antigen: a population-based study.

Authors:  Halcyon G Skinner; Gary G Schwartz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-10-27       Impact factor: 4.254

6.  Prostate cancer old problems and new approaches : Part I. epidemiology, incidence and genetic alterations.

Authors:  K V Honn; A Aref; Y Q Chen; M L Cher; J D Crissman; J D Forman; X Gao; D Grignon; M Hussain; A T Porter; J E Pontes; I Powell; B Redman; W Sakr; R Severson; D G Tang; D P Wood
Journal:  Pathol Oncol Res       Date:  1996-03       Impact factor: 3.201

7.  Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer.

Authors:  Steven Attia; Jens Eickhoff; George Wilding; Douglas McNeel; Jules Blank; Harish Ahuja; Alcee Jumonville; Michael Eastman; Daniel Shevrin; Michael Glode; Dona Alberti; Mary Jane Staab; Dottie Horvath; Jane Straus; Rebecca Marnocha; Glenn Liu
Journal:  Clin Cancer Res       Date:  2008-04-15       Impact factor: 12.531

8.  Bone mineral content and prostate cancer risk: data from the Baltimore Longitudinal Study of Aging.

Authors:  Stacy Loeb; H Ballentine Carter; Edward M Schaeffer; Shari M Ling; Anna Kettermann; Luigi Ferrucci; E Jeffrey Metter
Journal:  BJU Int       Date:  2010-01-06       Impact factor: 5.588

Review 9.  The role of complementary medicine in the treatment of prostate cancer.

Authors:  I Yip; N Duran
Journal:  Curr Urol Rep       Date:  2001-06       Impact factor: 3.092

10.  Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men.

Authors:  Christine M Barnett; Carrie M Nielson; Jackie Shannon; June M Chan; James M Shikany; Douglas C Bauer; Andrew R Hoffman; Elizabeth Barrett-Connor; Eric Orwoll; Tomasz M Beer
Journal:  Cancer Causes Control       Date:  2010-04-10       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.